AiCure

Drug Sponsors

Merck to acquire Sigma-Aldrich

Monday, September 22, 2014 02:31 PM

Merck has agreed to acquire Sigma-Aldrich, a St. Louis, Mo.-based life science and technology company, for $17 billion in an all-cash transaction.

More... »


Cubist opens international headquarters in Zurich

Monday, September 22, 2014 02:25 PM

Cubist Pharmaceuticals, a company focused on novel antibiotics, has announced the official opening of its international headquarters in Zurich, Switzerland. Located in a growing biopharmaceutical hub in Switzerland, the company's international operations complement its corporate headquarters in Lexington, Mass.

More... »

CenterWatch

Nanobiotix expands into the U.S.

Monday, September 22, 2014 02:24 PM

Nanobiotix, a Paris-headquartered clinical-stage nanomedicine company, has opened its first U.S. office in Boston.

More... »

GlaxoSmithKline to pay $485.2M fine to Chinese government in bribery scandal

Friday, September 19, 2014 01:31 PM

GlaxoSmithKline has confirmed the Changsha Intermediate People’s Court in Hunan Province, China ruled GSK China Investment (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and has been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China’s Ministry of Public Security in June 2013. 

More... »

Evotec takes legal steps against Andromeda Biotech

Friday, September 19, 2014 01:26 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, will take legal steps against Israel-based Andromeda Biotech to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277.

More... »

Bayer plans to focus entirely on life science businesses

Thursday, September 18, 2014 01:27 PM

Bayer has announced that it intends, in the future, to focus entirely on its life science businesses—HealthCare and CropScience—and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a human, animal and plant health company. The supervisory board unanimously has approved the board of management's plans.

More... »

AstraZeneca, Eli Lilly ink agreement for AZD3293 for Alzheimer’s disease

Wednesday, September 17, 2014 02:28 PM

AstraZeneca and Eli Lilly have inked an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.

More... »

Endo International seeks to acquire Auxilium Pharmaceuticals for $2.2B

Wednesday, September 17, 2014 02:12 PM

Endo International, a Dublin-based global specialty healthcare company, has delivered an unsolicited proposal to acquire all of the outstanding shares of Chesterbrook, Pa.-based Auxilium Pharmaceuticals for a per share consideration of $28.10, in a cash and stock transaction valued at $2.2 billion.

More... »

Novartis to open Center for Advanced Cellular Therapeutics at University of Pennsylvania

Monday, September 15, 2014 12:29 PM

The University of Pennsylvania’s alliance with Novartis has unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

More... »

Livongo Health launched

Wednesday, September 10, 2014 03:00 PM

Livongo Health, a California-based consumer digital health company, has launched with a vision to empower people with chronic conditions to live better through the combined power of technology, real-time personalized information and support from a chosen care team.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs